SCHEDULE 13G/A: Commodore Capital Discloses 2% Stake in Cidara Therapeutics

Commodore Capital LP and its affiliates have reported a 2.0% beneficial ownership stake in Cidara Therapeutics, Inc., totaling 585,000 shares of common stock.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively beneficially own 585,000 shares of Cidara Therapeutics, Inc. common stock.
• This ownership represents a 2.0% stake in Cidara Therapeutics, Inc.
• The ownership percentage is calculated based on 29,335,397 common shares reported as issued and outstanding by Cidara Therapeutics, Inc. as of September 30, 2025.
• The reporting persons explicitly state that the securities were not acquired or held for the purpose of changing or influencing the control of Cidara Therapeutics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of beneficial ownership below the control threshold, with no stated intent to influence management or operations, thus indicating a neutral sentiment.

Positives

• A notable institutional investor, Commodore Capital, has taken a position in Cidara Therapeutics, which could be interpreted as a vote of confidence in the company's long-term prospects, although the stake is not controlling.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Cidara Therapeutics, Inc.'s future performance or operations.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure of beneficial ownership and does not provide specific analysis of Cidara Therapeutics, Inc.'s position within its industry or broader industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's position, but the 2.0% stake is not typically considered a controlling or highly influential position.
• Management: The explicit statement that the stake is not for influencing control suggests no immediate challenge to current management or strategic direction.

Key Dates

Keywords

Cidara Therapeutics, Commodore Capital, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor, CDTX